MLLT11-TRIL complex promotes the progression of endometrial cancer through PI3K/AKT/mTOR signaling pathway

References

• Eritja N, Chen BJ, Rodriguez-Barrueco R, Santacana M, Gatius S, Vidal A, Martí MD, Ponce J, Bergadà L, Yeramian A, et al. Autophagy orchestrates adaptive responses to targeted therapy in endometrial cancer. Autophagy. 2017;13(3):608–624. doi:10.1080/15548627.2016.1271512. PMID:28055301.
   PubMed Web of Science ®Google Scholar
• Siegel RL, Miller KD, Jemal A. Cancer statistics, 2018. CA Cancer J Clin. 2018;68(1):7–30. doi:10.3322/caac.21442. PMID:29313949.
   PubMed Web of Science ®Google Scholar
• Leskela S, Perez-Mies B, Rosa-Rosa JM, Cristobal E, Biscuola M, Palacios-Berraquero ML. Molecular basis of tumor heterogeneity in endometrial carcinosarcoma. Cancers (Basel). 2019;11(7):964. doi:10.3390/cancers11070964. PMID:31324031.
   PubMed Web of Science ®Google Scholar
• Yeramian A, Moreno-Bueno G, Dolcet X, Catasus L, Abal M, Colas E, Reventos J, Palacios J, Prat J, Matias-Guiu X, et al. Endometrial carcinoma: molecular alterations involved in tumor development and progression. Oncogene. 2013;32(4):403–413. doi:10.1038/onc.2012.76. PMID:22430211.
   PubMed Web of Science ®Google Scholar
• Song J, Chen W, Zhu G, Wang W, Sun F, Zhu J. Immunogenomic profiling and classification of prostate cancer based on HIF-1 signaling pathway. Front Oncol. 2020;10:1374. doi:10.3389/fonc.2020.01374. PMID:32850440.
   PubMed Web of Science ®Google Scholar
• Bokhman JV. Two pathogenetic types of endometrial carcinoma. Gynecol Oncol. 1983;15(1):10–17. doi:10.1016/0090-8258(83)90111-7. PMID:6822361.
   PubMed Web of Science ®Google Scholar
• Elmenier FM, Lasheen DS, Abouzid K. Phosphatidylinositol 3 kinase (PI3K) inhibitors as new weapon to combat cancer. Eur J Med Chem. 2019;183:111718. doi:10.1016/j.ejmech.2019.111718. PMID:31581005.
   PubMed Web of Science ®Google Scholar
• Hers I, Vincent EE, Tavare JM. Akt signalling in health and disease. Cell Signal. 2011;23(10):1515–1527. doi:10.1016/j.cellsig.2011.05.004. PMID:21620960.
   PubMed Web of Science ®Google Scholar
• Heron-Milhavet L, Khouya N, Fernandez A, Lamb NJ. Akt1 and Akt2: differentiating the aktion. Histol Histopathol. 2011;26(5):651–662. doi:10.14670/HH-26.651. PMID:21432781.
   PubMed Web of Science ®Google Scholar
• Ding Z, Liang J, Li J, Lu Y, Ariyaratna V, Lu Z, Davies MA, Westwick JK, and Mills GB . Physical association of PDK1 with AKT1 is sufficient for pathway activation independent of membrane localization and phosphatidylinositol 3 kinase. Plos One. 2010;5(3):e9910. doi:10.1371/journal.pone.0009910. PMID:20361045.
   PubMed Web of Science ®Google Scholar
• Vejux A, Guyot S, Montange T, Riedinger JM, Kahn E, Lizard G. Phospholipidosis and down-regulation of the PI3-K/PDK-1/Akt signalling pathway are vitamin E inhibitable events associated with 7-ketocholesterol-induced apoptosis. J Nutr Biochem. 2009;20(1):45–61. doi:10.1016/j.jnutbio.2007.12.001. PMID:18495460.
   PubMed Web of Science ®Google Scholar
• Di Maira G, Brustolon F, Pinna LA, Ruzzene M. Dephosphorylation and inactivation of Akt/PKB is counteracted by protein kinase CK2 in HEK 293T cells. Cell Mol Life Sci. 2009;66(20):3363–3373. doi:10.1007/s00018-009-0108-1. PMID:19662498.
   PubMed Web of Science ®Google Scholar
• Tse W, Zhu W, Chen HS, Cohen A. A novel gene, AF1q, fused to MLL in t(1;11) (q21;q23), is specifically expressed in leukemic and immature hematopoietic cells. Blood. 1995;85(3):650–656. doi:10.1182/blood.V85.3.650.bloodjournal853650. PMID:7833468.
   PubMed Web of Science ®Google Scholar
• Park J, Schlederer M, Schreiber M, Ice R, Merkel O, Bilban M, Hofbauer S, Kim S, Addison J, Zou J, et al. AF1q is a novel TCF7 co-factor which activates CD44 and promotes breast cancer metastasis. Oncotarget. 2015;6(24):20697–20710. doi:10.18632/oncotarget.4136. PMID:26079538.
   PubMedGoogle Scholar
• Hu J, Li G, Liu L, Wang Y, Li X, Gong J. AF1q mediates tumor progression in colorectal cancer by regulating AKT signaling. Int J Mol Sci. 2017;18(5):987. doi:10.3390/ijms18050987. PMID:28475127.
   PubMed Web of Science ®Google Scholar
• Man G, Duan A, Liu W, Cheng J, Liu Y, Song J, Zhou H, Shen K. Circular RNA-related CeRNA network and prognostic signature for patients with osteosarcoma. Cancer Manag Res. 2021;13:7527–7541. doi:10.2147/CMAR.S328559. PMID:34629900.
   PubMed Web of Science ®Google Scholar
• Carpenter S, Carlson T, Dellacasagrande J, Garcia A, Gibbons S, Hertzog P, Lyons A, Lin L-L, Lynch M, Monie T, et al. TRIL, a functional component of the TLR4 signaling complex, highly expressed in brain. J Immunol. 2009;183(6):3989–3995. doi:10.4049/jimmunol.0901518. PMID:19710467.
   PubMed Web of Science ®Google Scholar
• Wang M, Liao J, Wang J, Qi M, Wang K, Wu W. TAF1A and ZBTB41 serve as novel key genes in cervical cancer identified by integrated approaches. Cancer Gene Ther. 2021;28(12):1298–1311. doi:10.1038/s41417-020-00278-1. PMID:33311601.
   PubMed Web of Science ®Google Scholar
• Shaul YD, Yuan B, Thiru P, Nutter-Upham A, McCallum S, Lanzkron C, Bell GW, Sabatini DM. MERAV: a tool for comparing gene expression across human tissues and cell types. Nucleic Acids Res. 2016;44(D1):D560–D566. doi:10.1093/nar/gkv1337. PMID:26626150.
   PubMed Web of Science ®Google Scholar
• Tomczak K, Czerwinska P, Wiznerowicz M. The Cancer Genome Atlas (TCGA): an immeasurable source of knowledge. Contemp Oncol (Pozn). 2015;19(1A):A68–A77. doi:10.5114/wo.2014.47136. PMID:25691825.
   PubMedGoogle Scholar
• Wang M, Wang J, Liu J, Zhu L, Ma H, Zou J, Wu W, Wang K. Systematic prediction of key genes for ovarian cancer by co-expression network analysis. J Cell Mol Med. 2020;24(11):6298–6307. doi:10.1111/jcmm.15271. PMID:32319226.
   PubMed Web of Science ®Google Scholar
• Raudvere U, Kolberg L, Kuzmin I, Arak T, Adler P, Peterson H, Vilo J. g:Profiler: a web server for functional enrichment analysis and conversions of gene lists (2019 update). Nucleic Acids Res. 2019;47(W1):W191–W198. doi:10.1093/nar/gkz369. PMID:31066453.
   PubMed Web of Science ®Google Scholar
• Wang M, Liao J, Tan C, Zhou H, Wang J, Wang K, Li Y, Wu W. Integrated study of miR-215 promoting breast cancer cell apoptosis by targeting RAD54B. J Cell Mol Med. 2021;25(7):3327–3338. doi:10.1111/jcmm.16402. PMID:33635591.
   PubMed Web of Science ®Google Scholar
• Liao J, Liu J, Wang J, Wang M. Lnc-CPLC promotes the progression of colorectal cancer via regulating ZBTB34 by competitively binding miR-4319. J Cell Physiol. 2021. doi:10.1002/jcp.30628. PMID:34741317.
   Web of Science ®Google Scholar
• Kim DE, Chivian D, Baker D. Protein structure prediction and analysis using the Robetta server. Nucleic Acids Res. 2004;32( Web Server issue):W526–W531. doi:10.1093/nar/gkh468. PMID:15215442.
   PubMed Web of Science ®Google Scholar
• Aoki M, Fujishita T. Oncogenic Roles of the PI3K/AKT/mTOR Axis. Curr Top Microbiol Immunol. 2017;407:153–189. doi:10.1007/82_2017_6. PMID:28550454.
   PubMed Web of Science ®Google Scholar
• Sorolla MA, Parisi E, Sorolla A. Determinants of sensitivity to radiotherapy in endometrial cancer. Cancers (Basel). 2020;12(7):1906. doi:10.3390/cancers12071906. PMID:32679719.
   PubMed Web of Science ®Google Scholar
• Miyasaka A, Oda K, Ikeda Y, Sone K, Fukuda T, Inaba K, Makii C, Enomoto A, Hosoya N, Tanikawa M, et al. PI3K/mTOR pathway inhibition overcomes radioresistance via suppression of the HIF1-alpha/VEGF pathway in endometrial cancer. Gynecol Oncol. 2015;138(1):174–180. doi:10.1016/j.ygyno.2015.04.015. PMID:25913131.
   PubMed Web of Science ®Google Scholar
• Roncolato F, Lindemann K, Willson ML, Martyn J, Mileshkin L. PI3K/AKT/mTOR inhibitors for advanced or recurrent endometrial cancer. Cochrane Database Syst Rev. 2019;10:D12160. doi:10.1002/14651858.CD012160.pub2. PMID:31588998.
   Google Scholar
• Barra F, Evangelisti G, Ferro DL, Di Domenico S, Ferraioli D, Vellone VG, De Cian F, Ferrero S. Investigational PI3K/AKT/mTOR inhibitors in development for endometrial cancer. Expert Opin Investig Drugs. 2019;28(2):131–142. doi:10.1080/13543784.2018.1558202. PMID:30574817.
   PubMed Web of Science ®Google Scholar
• Majchrzak-Baczmanska D, Malinowski A. Does IGF-1 play a role in the biology of endometrial cancer? Ginekol Pol. 2016;87(8):598–604. doi:10.5603/GP.2016.0052. PMID:27629137.
   PubMed Web of Science ®Google Scholar
• Kwasniewski W, Gozdzicka-Jozefiak A, Wolun-Cholewa M, Polak G, Sierocinska-Sawa J, Kwasniewska A, Kotarski J. Microsatellite polymorphism in the P1 promoter region of the IGF-1 gene is associated with endometrial cancer. Mol Med Rep. 2016;13(6):4950–4958. doi:10.3892/mmr.2016.5181. PMID:27121258.
   PubMed Web of Science ®Google Scholar
• Zhang Y, Li MX, Wang H, Zeng Z, Li XM. Metformin down-regulates endometrial carcinoma cell secretion of IGF-1 and expression of IGF-1R. Asian Pac J Cancer Prev. 2015;16(1):221–225. doi:10.7314/apjcp.2015.16.1.221. PMID:25640355.
   PubMedGoogle Scholar
• Anisimov VN, Bartke A. The key role of growth hormone–insulin–IGF-1 signaling in aging and cancer. Crit Rev Oncol Hematol. 2013;87(3):201–223. doi:10.1016/j.critrevonc.2013.01.005. PMID:23434537.
   PubMed Web of Science ®Google Scholar
• Majchrzak-Baczmanska D, Malinowski A, Glowacka E, Wilczynski M. Does IGF-1 play a role in the biology of ovarian cancer? Ginekol Pol. 2018;89(1):13–19. doi:10.5603/GP.a2018.0003. PMID:29411341.
   PubMed Web of Science ®Google Scholar
• Min DY, Jung E, Kim J, Lee YH, Shin SY. Leptin stimulates IGF-1 transcription by activating AP-1 in human breast cancer cells. BMB REP. 2019;52(6):385–390. doi:10.5483/BMBRep.2019.52.6.189. PMID:30293548.
   PubMed Web of Science ®Google Scholar
• Roberts CJ. IGF-1 and prostate cancer. Novartis Found Symp. 2004;262:193–199, 199–204, 265–268. PMID:15562830.
   PubMedGoogle Scholar
• Lonning PE, Helle SI. IGF-1 and breast cancer. Novartis Found Symp. 2004;262:205–212, 212–214, 265–268. PMID:15562831.
   PubMedGoogle Scholar
• Yang L, Wang H, Liu L, Xie A. The role of Insulin/IGF-1/PI3K/Akt/GSK3beta signaling in Parkinson’s disease dementia. Front Neurosci. 2018;12:73. doi:10.3389/fnins.2018.00073. PMID:29515352.
   PubMed Web of Science ®Google Scholar
• Timmer LT, Hoogaars W, Jaspers RT. The role of IGF-1 signaling in skeletal muscle atrophy. Adv Exp Med Biol. 2018;1088:109–137. doi:10.1007/978-981-13-1435-3_6. PMID:30390250.
   PubMed Web of Science ®Google Scholar
• Rong L, Li Z, Leng X, Li H, Ma Y, Chen Y, Song F. Salidroside induces apoptosis and protective autophagy in human gastric cancer AGS cells through the PI3K/Akt/mTOR pathway. Biomed Pharmacother. 2020;122:109726. doi:10.1016/j.biopha.2019.109726. PMID:31918283.
   PubMed Web of Science ®Google Scholar
• Ersahin T, Tuncbag N, Cetin-Atalay R. The PI3K/AKT/mTOR interactive pathway. Mol Biosyst. 2015;11(7):1946–1954. doi:10.1039/c5mb00101c. PMID:25924008.
   PubMedGoogle Scholar
• Yuan Y, Fan Y, Gao Z, Sun X, Zhang H, Wang Z, Cui Y, Song W, Wang Z, Zhang F, et al. SHP2 promotes proliferation of breast cancer cells through regulating Cyclin D1 stability via the PI3K/AKT/GSK3beta signaling pathway. Cancer Biol Med. 2020;17(3):707–725. doi:10.20892/j.2095-3941.2020.0056. PMID:32944401.
   PubMed Web of Science ®Google Scholar
• Xu S, Zhang H, Liu T, Yang W, Lv W, He D, Guo P, Li L. 6-Gingerol induces cell-cycle G1-phase arrest through AKT-GSK 3beta-cyclin D1 pathway in renal-cell carcinoma. Cancer Chemother Pharmacol. 2020;85(2):379–390. doi:10.1007/s00280-019-03999-9. PMID:31832810.
   PubMed Web of Science ®Google Scholar
• Wang E, Sorolla A. Sensitizing endometrial cancer to ionizing radiation by multi-tyrosine kinase inhibition. J Gynecol Oncol. 2020;31(3):e29. doi:10.3802/jgo.2020.31.e29. PMID:31912683.
   PubMed Web of Science ®Google Scholar
• Hirai H, Sootome H, Nakatsuru Y, Miyama K, Taguchi S, Tsujioka K, Ueno Y, Hatch H, Majumder PK, Pan B-S, et al. MK-2206, an allosteric akt inhibitor, enhances antitumor efficacy by standard chemotherapeutic agents or molecular targeted drugs in vitro and in vivo. Mol Cancer Ther. 2010;9(7):1956–1967. doi:10.1158/1535-7163.MCT-09-1012. PMID:20571069.
   PubMed Web of Science ®Google Scholar
• Khan N, Park J, Dean WL, Gray RD, Tse W, Lee D, Sabo TM. Recombinant expression and purification of AF1q and its interaction with T-cell Factor 7. Protein Expr Purif. 2020;165:105499. doi:10.1016/j.pep.2019.105499. PMID:31541685.
   PubMed Web of Science ®Google Scholar
• Gruber ES, Oberhuber G, Birner P, Schlederer M, Kenn M, Schreiner W, Jomrich G, Schoppmann SF, Gnant M, and Tse W. The oncogene AF1Q is associated with WNT and STAT signaling and offers a novel independent prognostic marker in patients with resectable esophageal cancer. Cells-Basel. 2019;8(11). doi:10.3390/cells8111357. PMID:31671695.
   Google Scholar
• Jia H, Ma H, Li Z, Chen F, Fang B, Cao X, Chang Y, Qiang Z. Downregulation of LncRNA TUG1 inhibited TLR4 signaling pathway-mediated inflammatory damage after spinal cord ischemia reperfusion in rats via suppressing TRIL expression. J Neuropathol ExpNeurol.2019;78(3):268–282.doi:10.1093/jnen/nly126. PMID:30715406.
   PubMed Web of Science ®Google Scholar